Los Angeles Capital Management LLC Has $11.40 Million Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX)

Los Angeles Capital Management LLC trimmed its stake in shares of Royalty Pharma plc (NASDAQ:RPRX) by 5.9% in the 4th quarter, HoldingsChannel reports. The firm owned 405,971 shares of the biopharmaceutical company’s stock after selling 25,575 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Royalty Pharma were worth $11,404,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Allworth Financial LP boosted its stake in Royalty Pharma by 89.8% in the 3rd quarter. Allworth Financial LP now owns 953 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 451 shares during the period. EverSource Wealth Advisors LLC lifted its holdings in shares of Royalty Pharma by 112.0% in the third quarter. EverSource Wealth Advisors LLC now owns 1,005 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 531 shares in the last quarter. Lindbrook Capital LLC boosted its position in shares of Royalty Pharma by 485.2% in the fourth quarter. Lindbrook Capital LLC now owns 2,411 shares of the biopharmaceutical company’s stock worth $68,000 after buying an additional 1,999 shares during the period. Rakuten Securities Inc. purchased a new position in shares of Royalty Pharma during the fourth quarter valued at $110,000. Finally, PNC Financial Services Group Inc. lifted its position in shares of Royalty Pharma by 10.8% in the third quarter. PNC Financial Services Group Inc. now owns 5,509 shares of the biopharmaceutical company’s stock worth $150,000 after purchasing an additional 536 shares in the last quarter. Institutional investors and hedge funds own 54.35% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on RPRX. StockNews.com raised shares of Royalty Pharma from a “hold” rating to a “buy” rating in a research note on Thursday, April 11th. JPMorgan Chase & Co. dropped their price target on shares of Royalty Pharma from $45.00 to $42.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 20th. The Goldman Sachs Group reduced their price objective on shares of Royalty Pharma from $56.00 to $50.00 and set a “buy” rating for the company in a research note on Tuesday, February 20th. Finally, Bank of America decreased their price objective on shares of Royalty Pharma from $40.00 to $38.00 and set a “buy” rating for the company in a report on Friday, April 12th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Royalty Pharma presently has an average rating of “Buy” and an average price target of $46.75.

Royalty Pharma Stock Down 1.2 %

Shares of Royalty Pharma stock opened at $28.41 on Friday. Royalty Pharma plc has a 12-month low of $25.92 and a 12-month high of $35.70. The stock has a market capitalization of $16.97 billion, a P/E ratio of 15.03 and a beta of 0.47. The company has a quick ratio of 7.90, a current ratio of 7.90 and a debt-to-equity ratio of 0.61. The stock has a 50 day moving average price of $29.36 and a two-hundred day moving average price of $28.58.

Royalty Pharma (NASDAQ:RPRX) last posted its quarterly earnings data on Thursday, February 15th. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.03 by $0.12. Royalty Pharma had a net margin of 48.22% and a return on equity of 26.93%. The business had revenue of $736.00 million during the quarter, compared to the consensus estimate of $702.90 million. Equities analysts expect that Royalty Pharma plc will post 3.95 earnings per share for the current year.

Royalty Pharma Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 17th will be issued a dividend of $0.21 per share. This represents a $0.84 dividend on an annualized basis and a yield of 2.96%. The ex-dividend date is Thursday, May 16th. Royalty Pharma’s dividend payout ratio (DPR) is 44.44%.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.